InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. InnoCare' s core scientific team membe have strong educational backgrounds and rich drug innovation experiences in the U.S. and China. InnoCare also has an elite Scientific Advisory Board (SAB) comprising of professionals from leading univeities, hospitals, academic ititutio and pharmaceutical industry. InnoCare is forging forward on the critical path of defeating diseases and pushing the boundaries of innovation into unchartered territories.

The mission of InnoCare is to become a global leader in providing patients with safe, effective and affordable treatments to address the unmet medical needs in cancer and autoimmune diseases. We pay special attention in targeting Chinese populatio because of their high incidence rates yet iufficient effective treatments or cures for diseases such as liver cancer, gastrointestinal cancer, and autoimmune diseases including lupus and rheumatoid arthritis. To achieve our goal, we have employed numerous synergistic approaches including internal research and development, liceing-in, and international collaboratio to accelerate the development process of the Fit- and/or Best-in-Class drugs.

诺诚健华是一家植根于中国且具全球视野的新药创制公司。公司的核心团队都具有丰富的新药研发经验，曾成功开发出超过100个新药专利和候选新药。公司的科学顾问委员会由来自清华、北大的生命科学带头人、跨国公司新药研发专家以及国内顶尖医院的医疗专家组成。他们与公司的研发团队一起，构成公司的核心竞争力。

面对在中国发病率居高不下且缺乏有效治疗的肝癌、胃癌及类风湿关节炎、系统性红斑狼疮等自身免疫疾病，诺诚健华自创立之日起，就把“利用最新的科学技术与发现驱动新药研发，提供患者治疗所需的新药，为改善公众健康而努力”作为自己的使命。为达成这一使命，我们专注于国际一类新药与新技术产品开发，通过“自主研发、外部引进与国际合作”等途径，有效整合各方资源并加快新药研究在中国从实验室到医院的进程，在帮助中国患者尽早用到国际一类新药的同时，把公司打造成国内外生物医药行业的领军企业。